MB-CAR-T19-22 / Miltenyi Biotec - LARVOL DELTA

CD19/CD22 CAR-T cells in adult patients with relapsed/refractory B-cell malignancies (ASH 2025) - "Lymphodepletion was performed using fludarabine (25mg/m²/day, days –5 to –3) and cyclophosphamide (1000 mg/m², day –3). The investigational CD19/CD22-targeted CAR-T cell product demonstrated encouragingefficacy with a manageable safety profile in heavily pretreated adult patients with relapsed/refractory B-cell malignancies, including post-transplant settings. Dual targeting may offer therapeutic advantages inovercoming antigen escape and achieving durable remissions. Based on promising results, a Phase Idose-finding and efficacy study of a third-generation CAR-T cell product (MB-CART19.22), is planned inadult and pediatric patients with relapsed or refractory B-cell malignancies."

CAR T-Cell Therapy • Clinical • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Graft versus Host Disease • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Immunology • Infectious Disease • Leukemia • Lymphoma • Mantle Cell Lymphoma • Mediastinal B Cell Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma • Rare Diseases • Richter's Syndrome • Septic Shock • Squamous Cell Carcinoma • CD22

Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL (clinicaltrials.gov) - P1/2 | N=50 | Active, not recruiting | Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2025 ➔ Mar 2027 | Trial primary completion date: Dec 2022 ➔ Mar 2022

Enrollment closed • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • Pediatrics • CD19 • CD22